Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

ATB200-02: Phase I/II

Treating: Pompe Disease

Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III

Treating: Axial Spondyloarthritis

Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CAIN457K2340: Phase III

Treating: Axial Spondyloarthritis

Indication: Active radiographic Axial Spondyloarthritis
Status: Open and Currently Enrolling
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis

D1699C00001: Phase III

Treating: Heart Failure

Indication: Chronic Heart Failure with Reduced Ejection Fraction
Status: Open/Currently Not Enrolling
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

D169CC00001 (Deliver-HF): Phase III

Treating: Heart Failure

Status: Open/Currently enrolling
An international, double-blind, randomized, placebo-controlled phase III study to evaluate the effect of Dapagliflozin on reducing CV death or worsening heart failure in patient with heart failure with preserved ejection fraction (HFpEF)

EFC14828 (Amplitude-O): Phase III

Treating: Diabetes

Status: Open/Currently enrolling
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of Efpeglenatide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk

Announcements

News & Events

Awards

Meet Our Providers

Brandon McCafferty, MD

Ophthalmology

Optical Center

Vision Center

Andrew Lindekugel, DPM

Ambulatory Surgery Center

Podiatry / Podiatric Surgery

Becky Wozniak, DNP

Family Practice

Andrea Withey, RDN

Endocrinology